Journal article
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor
Abstract
The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition.
Authors
Prasit P; Wang Z; Brideau C; Chan C-C; Charleson S; Cromlish W; Ethier D; Evans JF; Ford-Hutchinson AW; Gauthier JY
Journal
Bioorganic & Medicinal Chemistry Letters, Vol. 9, No. 13, pp. 1773–1778
Publisher
Elsevier
Publication Date
7 1999
DOI
10.1016/s0960-894x(99)00288-7
ISSN
0960-894X